Skip to main content

Class Action Alleges Valsartan As An Unapproved Drug

Class Action Alleges Valsartan As An Unapproved Drug

Class Action Alleges Valsartan As An Unapproved Drug

Introduction

The valsartan class action lawsuit has alleged that the recalled generic versions of the blood pressure medication distributed in recent years should be considered as an unapproved drug due to the presence of carcinogenic impurities.

According to a complaint filed last week in the U.S. District Court for the District of New Jersey, the plaintiff has alleged that the valsartan manufacturers illegally sold contaminated drugs and falsely advertised them as generic valsartan equivalents, cheating hundreds of thousands of consumers and putting their health at risk. The allegations were on behalf of all Florida residents who purchased recalled generic valsartan products manufactured and distributed by Zhejiang Huahai Pharmaceutical Co., Ltd., Solco Healthcare U.S., and Prinston Pharmaceutical, Inc., who are all defendants in the claim.

There are currently 10 class action lawsuits and one individual action pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!